1150271-33-2 Usage
Uses
Used in Pharmaceutical Research:
Benzyl4-(4-bromophenyl)piperazine-1-carboxylate is used as a precursor in the synthesis of potential medications for psychiatric disorders and neurological conditions. Its unique structure and properties make it a valuable component in the development of new therapeutic agents.
Used in Drug Discovery and Development:
As a versatile compound, Benzyl4-(4-bromophenyl)piperazine-1-carboxylate is used as a building block in the synthesis of diverse bioactive molecules. Its potential for creating new and effective pharmaceutical compounds makes it an important asset in the field of drug discovery and development.
Used in Chemical Synthesis:
Benzyl4-(4-bromophenyl)piperazine-1-carboxylate is used as a key intermediate in the chemical synthesis of various compounds. Its reactivity and compatibility with other chemical groups make it a useful component in the creation of complex molecules for a wide range of applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1150271-33-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,0,2,7 and 1 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1150271-33:
(9*1)+(8*1)+(7*5)+(6*0)+(5*2)+(4*7)+(3*1)+(2*3)+(1*3)=102
102 % 10 = 2
So 1150271-33-2 is a valid CAS Registry Number.
1150271-33-2Relevant academic research and scientific papers
GLYCINE COMPOUND
-
Page/Page column 24, (2012/07/28)
[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.
TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
-
Page/Page column 32, (2011/02/15)
The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.
